Related references
Note: Only part of the references are listed.Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma
Byeong-Joo Noh et al.
BMC CANCER (2020)
Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS
Jing Wang et al.
MODERN PATHOLOGY (2019)
PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1
Hsiang-Ling Ho et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling
Svetlana Kintsler et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2019)
Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions
U. Bender et al.
CURRENT ONCOLOGY (2019)
Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer
Sumana Narayanan et al.
SCIENTIFIC REPORTS (2019)
Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis
Zefeng Shen et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2019)
PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry
Tony El Jabbour et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Expression Profile of LGR5 and Its Prognostic Significance in Colorectal Cancer Progression
Bo Gun Jang et al.
AMERICAN JOURNAL OF PATHOLOGY (2018)
Poorly Differentiated Clusters Predict Colon Cancer Recurrence An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers
Tsuyoshi Konishi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Targeting LGR5 in Colorectal Cancer: therapeutic gold or too plastic?
R. G. Morgan et al.
BRITISH JOURNAL OF CANCER (2018)
Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer
Lisha Wang et al.
HUMAN PATHOLOGY (2018)
TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas
Tsuyoshi Hamada et al.
ONCOIMMUNOLOGY (2018)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer
Shigehiro Koganemaru et al.
CANCER SCIENCE (2017)
Lgr5 expression is a valuable prognostic factor for colorectal cancer: evidence from a meta-analysis
Yangyan Jiang et al.
BMC CANCER (2016)
Tumor budding in colorectal cancer-ready for diagnostic practice?*'**
Viktor H. Koelzer et al.
HUMAN PATHOLOGY (2016)
Cancer stem cells Role in tumor growth, recurrence, metastasis, and treatment resistance
Jenny C. Chang
MEDICINE (2016)
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
Matthew W. Rosenbaum et al.
MODERN PATHOLOGY (2016)
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Andreas H. Scheel et al.
MODERN PATHOLOGY (2016)
Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer
Lisha Wang et al.
MOLECULAR DIAGNOSIS & THERAPY (2016)
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Kim C. Ohaegbulam et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance
Songbing He et al.
BIOMEDICINE & PHARMACOTHERAPY (2014)
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
Zoran Gatalica et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
In situ validation of an intestinal stem cell signature in colorectal cancer
Jennifer L. Ziskin et al.
GUT (2013)
Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival
Xiao-Song Wu et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2012)
Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer
Hiroshi Uchida et al.
CANCER SCIENCE (2010)
Invasive front of colorectal cancer: Dynamic interface of pro-/anti-tumor factors
Inti Zlobec et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Identification of stem cells in small intestine and colon by marker gene Lgr5
Nick Barker et al.
NATURE (2007)
Prospective identification of tumorigenic breast cancer cells
M Al-Hajj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
